萊美藥業(300006.SZ)擬受讓愛甲專線部分股權並對核心管理團隊進行股權激勵
格隆匯 2 月 8日丨萊美藥業(300006.SZ)公佈，公司控股子公司愛甲專線健康管理有限公司(“愛甲專線”)以甲狀腺專科疾病管理為業務核心，專注於服務細分領域用户，並提供線上線下相結合的健康管理服務。為加快推進打造甲狀腺疾病領域頭部企業的戰略目標，促進愛甲專線快速健康發展，公司於2021年2月5日召開的第五屆董事會第十二次會議和第五屆監事會第九次會議分別審議通過了《關於受讓子公司部分股權及股權激勵的議案》，同意公司受讓愛甲專線其他少數股東股權並對愛甲專線核心團隊進行股權激勵。
鑑於汪徐已向目標公司實繳出資187萬元，汪徐同意以人民幣140.25萬元將其持有目標公司30%股權轉讓給公司，汪徐同意以人民幣46.75萬元將其持有目標公司10%股權轉讓給西藏天恩企業管理諮詢合夥企業(有限合夥)，公司和西藏天恩企業管理諮詢合夥企業(有限合夥)均同意以上述轉讓價格分別受讓對應股權。公司和西藏天恩企業管理諮詢合夥企業(有限合夥)同意本協議簽署生效後5個工作日內按受讓股權比例分別支付給汪徐人民幣140.25萬元、46.75萬元。
公司經多年發展在甲狀腺疾病領域積累了豐富的專家、患者資源，搭建了成熟的甲狀腺疾病管理平台。基於上述相關資源，控股子公司愛甲專線通過醫生、患者、平台三方良性互動，構建了甲狀腺疾病管理生態圈。目前，愛甲專線已先後在全國部分省市設立了線下實體甲狀腺健康管理中心，後續愛甲專線將持續推進在全國各省市的甲狀腺健康管理中心建設工作，進一步提升平台簽約甲狀腺專家和i甲專線公眾號關注數量，助力公司打造成為甲狀腺疾病領域頭部企業。
此次公司受讓愛甲專線部分股權並對核心管理團隊進行股權激勵，有利於發揮愛甲專線核心管理團隊能動性，加快推進公司聚焦細分優勢領域的步伐，有利於公司打造甲狀腺疾病領域頭部企業戰略目標的實現和達成。根據協議約定，首次股權激勵實施完成後對公司2021年損益影響金額約為人民幣-675萬元，最終數據將以經審計的財務報吿數據為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
